# Bisoprolol

## CONCOR 5mg

##### 

| TAH Drug Code      | [OCON](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OCON)                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 1.25 mg & 2.5 mg tab Stable chronic moderate to severe heart failure. 5 mg & 10 mg tab Management of hypertension, angina pectoris & stable, chronic moderate to severe heart failure (NYHA class III, IV).                                                                                                                                                                                                                                                                                                |
| Dosing             | Hypertension, angina: Initially 5mg QD, may up to 10mg QD if needed. Maximum: 20mg QD. Stable mild to server chronic heart failure: Patient must be treated at an optimal dose with an ACE inhibitor, a diuretic, & optionally cardiac glycosides, prior to the administration of bisoprolol. Titrate gradually as follows: Week 1: 1.25 mg QD. Week 2: 2.5 mg QD. Week 3: 3.75 mg QD. Week 4-7: 5 mg QD. Week 8-11: 7.5 mg QD. Week 12 and beyond: 10 mg QD as maintenance therapy. Maximum: 10 mg daily. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Acute heart failure or during episodes of heart failure decompensation requiring IV inotropic therapy, cardiogenic shock, AV block of grades II & III (without pacemaker), sick sinus syndrome, SA block, bradycardia with < 60 beats/min; severe bronchial asthma or severe COPD, hypotension (systolic BP < 100 mmHg), advanced stages of peripheral arterial circulatory disturbance & Raynaud's syndrome, untreated pheochromocytoma, metabolic acidosis.                                              |
| Adverse Effects    | Feeling of coldness or numbness in the extremities, nausea, vomiting, diarrhea, constipation. Tiredness, exhaustion, dizziness, headache (occur at the beginning of the therapy & usually disappear within 1-2 weeks). Gastrointestinal: Diarrhea (2.6% to 3.5% ) Neurologic: Headache (8.8% to 10.9% ) Respiratory: Rhinitis (2.9% to 4% ), Upper respiratory infection (4.8% to 5% .) Other: Fatigue (6.6% to 8.2%)                                                                                      |
| Pregnancy          | Human Data Suggest Risk in 2nd and 3Rd Trimesters                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

## Concor 1.25mg康肯錠

##### 

| TAH Drug Code      | [OCON1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OCON1)                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | 1.25 mg & 2.5 mg tab Stable chronic moderate to severe heart failure. 5 mg & 10 mg tab Management of hypertension, angina pectoris & stable, chronic moderate to severe heart failure (NYHA class III, IV).                                                                                                                                                                                                                                                   |
| Dosing             | Stable mild to server chronic heart failure: Patient must be treated at optimal dose with an ACE inhibitor, a diuretic, & optionally cardiac glycosides, prior to the administration of bisoprolol. Titrate gradually as follows: Week 1: 1.25 mg QD. Week 2: 2.5 mg QD. Week 3: 3.75 mg QD. Week 4-7: 5 mg QD. Week 8-11: 7.5 mg QD. Week 12 and beyond: 10 mg QD as maintenance therapy. Maximum: 10 mg daily.                                              |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Contraindications  | Acute heart failure or during episodes of heart failure decompensation requiring IV inotropic therapy, cardiogenic shock, AV block of grades II & III (without pacemaker), sick sinus syndrome, SA block, bradycardia with < 60 beats/min; severe bronchial asthma or severe COPD, hypotension (systolic BP < 100 mmHg), advanced stages of peripheral arterial circulatory disturbance & Raynaud's syndrome, untreated pheochromocytoma, metabolic acidosis. |
| Adverse Effects    | Feeling of coldness or numbness in the extremities, nausea, vomiting, diarrhea, constipation. Tiredness, exhaustion, dizziness, headache (occur at the beginning of the therapy & usually disappear within 1-2 weeks). Gastrointestinal: Diarrhea (2.6% to 3.5% ) Neurologic: Headache (8.8% to 10.9% ) Respiratory: Rhinitis (2.9% to 4% ), Upper respiratory infection (4.8% to 5% .) Other: Fatigue (6.6% to 8.2%)                                         |
| Pregnancy          | Human Data Suggest Risk in 2nd and 3Rd Trimesters                                                                                                                                                                                                                                                                                                                                                                                                             |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                  |

